Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Real-world data support DOACs over warfarin for VTE
The direct oral anticoagulants (DOACs) apixaban and rivaroxaban trump warfarin for the treatment of venous thromboembolism (VTE) in a retrospective observational analysis comprising real-world VTE patients from Finland, Norway, and Sweden.
Real-world data support DOACs over warfarin for VTE
12 Jul 2024
DESTINY-Breast03 reports longest OS in previously treated HER2-positive mBC
Long-term follow-up of the DESTINY-Breast03 trial has reported a median overall survival (OS) of 52.6 months with trastuzumab deruxtecan (T-DXd), representing the longest reported OS in previously treated HER2-positive metastatic breast cancer (mBC) to date.
DESTINY-Breast03 reports longest OS in previously treated HER2-positive mBC
12 Jul 2024
Novel antireflux device shows potential for treatment of PPI-refractory GERD
Patients suffering from gastroesophageal reflux disease (GERD) and ineffective esophageal motility (IEM) may benefit from the novel RefluxStop device implantation, a safe and minimally invasive technology that offers potential benefits, a study has shown.
Novel antireflux device shows potential for treatment of PPI-refractory GERD
11 Jul 2024
Statin use tied to joint replacement risk
A French study presented at EULAR 2024 reveals an association between statin treatment and an increased risk of total joint replacement in individuals with knee and hip osteoarthritis (OA).
Statin use tied to joint replacement risk
11 Jul 2024
Kidney, heart benefits FLOW with semaglutide
Semaglutide reduces the risk of major kidney disease-related events and death from cardiovascular causes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), as shown in the FLOW* study presented at ERA 2024.